53295-44-6

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2,3-dihydro-5,6-dimethoxy-1-oxo-1H-indene-2-carboxylate is used as a potential pharmaceutical agent due to its unique molecular structure and the presence of functional groups that may contribute to medicinal properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Ethyl 2,3-dihydro-5,6-dimethoxy-1-oxo-1H-indene-2-carboxylate serves as a subject of study for its possible biological activities and interactions with biological targets, which could lead to the development of new drugs or therapeutic agents.

InChI:InChI=1/C14H16O5/c1-4-19-14(16)10-5-8-6-11(17-2)12(18-3)7-9(8)13(10)15/h6-7,10H,4-5H2,1-3H3

Upstream product

• 2107-69-9 5,6-dimethoxy-1-indanone 
• 105-58-8 Diethyl carbonate 
• 83-33-0 inden-1-one 
• 64-17-5 ethanol 
• 106648-24-2 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-indene-2-carbonitrile 

Downstream Products

• 1026724-41-3 2-{4-[Ethyl-(2-methoxy-benzyl)-amino]-butyl}-5,6-dimethoxy-1-oxo-indan-2-carboxylic acid ethyl ester 
• 132219-07-9 2-{5-[Ethyl-(2-methoxy-benzyl)-amino]-pentyl}-5,6-dimethoxy-1-oxo-indan-2-carboxylic acid ethyl ester 
• 1027584-13-9 2-{6-[Ethyl-(2-methoxy-benzyl)-amino]-hexyl}-5,6-dimethoxy-1-oxo-indan-2-carboxylic acid ethyl ester 
• 652130-42-2 1-benzyloxycarbonyl-4-[(5,6-dimethoxy-2-ethoxycarbonylindan-1-on-2-yl)methyl]piperidine 
• 1421022-34-5 (2RS)-2-{3-[(5S)-2-benzyloxy-5,6,7,8-tetrahydro-quinolin-5-ylamino]-propyl}-5,6-dimethoxy-indan-1-one 
• 1421022-38-9 (2RS)-2-{5-[(5S)-2-benzyloxy-5,6,7,8-tetrahydro-quinolin-5-ylamino]-pentyl}-5,6-dimethoxy-indan-1-one 
• 1421022-39-0 (2RS)-2-{6-[(5S)-2-benzyloxy-5,6,7,8-tetrahydro-quinolin-5-ylamino]-hexyl}-5,6-dimethoxy-indan-1-one 
• 1421022-40-3 (2RS)-2-{7-[(5S)-2-benzyloxy-5,6,7,8-tetrahydro-quinolin-5-yl-amino]-heptyl}-5,6-dimethoxy-indan-1-one 
• 1421022-41-4 (2RS)-2-{9-[(5S)-2-benzyloxy-5,6,7,8-tetrahydro-quinolin-5-ylamino]-nonyl}-5,6-dimethoxy-indan-1-one 
• 1609250-10-3 ethyl 5,6-dimethoxy-1-oxo-2-(3-phenylprop-2-ynyl)-2,3-dihydro-1H-indene-2-carboxylate 
• 1609250-11-4 ethyl 5,6-dimethoxy-1-oxo-2-(3-o-tolylprop-2-ynyl)-2,3-dihydro-1H-indene-2-carboxylate 
• 1609250-12-5 ethyl 5,6-dimethoxy-1-oxo-2-(3-m-tolylprop-2-ynyl)-2,3-dihydro-1H-indene-2-carboxylate 
• 1609250-13-6 ethyl 5,6-dimethoxy-2-(3-(2-methoxyphenyl) prop-2-ynyl)-1-oxo-2,3-dihydro-1Hindene-2-carboxylate 
• 1609250-14-7 ethyl 5,6-dimethoxy-2-(3-(4-methoxyphenyl)prop-2-ynyl)-1-oxo-2,3-dihydro-1H-indene-2-carboxylate 

Relevant academic research and scientific papers

Synthesis of indole based novel small molecules and their in vitro anti-proliferative effects on various cancer cell lines

Indole based novel small molecules were designed as potential anticancer agents. Multi step synthesis of these compounds was carried out by using Pd/C-Cu mediated coupling-cyclization strategy as a key step. The single crystal X-ray diffraction study was used to confirm the molecular structure of a representative compound unambiguously. Many of these compounds were evaluated for their anti-proliferative properties in vitro against six cancer cell lines as well as noncancerous cells. All these compounds showed selective growth inhibition of cancer cells and several of them were found to be promising with IC50 values in the range of 0.1-1.2 μM, comparable to the known anticancer drug doxorubicin.

Redetermination of the Structure of a Water-Soluble Hypervalent Iodine(V) Reagent AIBX and Its Synthetic Utility in the Oxidation of Alcohols and Synthesis of Isoxazoline N-Oxides

The structure of a water-soluble hypervalent iodine(V) reagent AIBX is re-examined through its single-crystal X-ray analysis and theoretical calculations including Mayer bond order and localized orbital locator (LOL) and AIBX is believed to be a pseudocyclic iodylarene because of the strong electron-withdrawing nature of the trimethylammonium cation on its phenyl ring, which would decrease the electron density of carboxylic anion and make the ortho-carboxyl oxygen anion incapable to form hypervalent bond with iodine atom. However, the cyclic benziodoxole structure of AIBX could be obtained by adding a Br?nsted acid, which was supported by the calculation result including the increase of Mayer bond order and the shortening of the I-O bond length. Moreover, the fact that the system of AIBX and TFA could oxidize various alcohols to their corresponding carbonyl compounds would indicate that AIBX constitutes a cyclic benziodoxole structure under acidic conditions. In addition, an efficient method has been developed for the synthesis of isoxazoline N-oxides via AIBX-induced dehydrogenative cyclization using β-keto esters as substrates and methyl nitroacetate as a nucleophile.

L-meptazinol indanone derivatives and/or salts thereof, and preparation method and application thereof

The invention relates to L-meptazinol indanone derivatives with a structure as shown in a general formula (I) which is described in the specification and/or salts thereof, and a preparation method and application thereof, belonging to the field of pharmacy. Pharmacological experiment results show that the L-meptazinol indanone derivatives and/or salts thereof have activity in inhibiting both acetylcholinesterase and Abeta aggregation and can be used for preparing drugs used for preventing and/or treating neurodegenerative diseases including the Alzheimer's disease (AD) and the Parkinson's disease (PD) and a variety of dementia diseases like AD, dementia with a lewy body (DLB) and vascular dementia (VaD). In the general formula (I), n is 2, 3, 4, 5, 6 or 7.

Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents

A compound of the formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and -CHR3- is =CH- linked by the double bond to the cyclopentanone; or -(-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N-heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR', CN, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halogen, heteroaryl; and the pharmaceutical salts or tautomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

Synthesis of indole based novel small molecules and their in vitro anti-proliferative effects on various cancer cell lines

Indole based novel small molecules were designed as potential anticancer agents. Multi step synthesis of these compounds was carried out by using Pd/C-Cu mediated coupling-cyclization strategy as a key step. The single crystal X-ray diffraction study was used to confirm the molecular structure of a representative compound unambiguously. Many of these compounds were evaluated for their anti-proliferative properties in vitro against six cancer cell lines as well as noncancerous cells. All these compounds showed selective growth inhibition of cancer cells and several of them were found to be promising with IC50 values in the range of 0.1-1.2 μM, comparable to the known anticancer drug doxorubicin.

Pd/C-mediated arylation followed by I2-catalyzed hydration strategy: Preparation of functionalized novel indanone derivatives

A simple and inexpensive synthesis of novel 2-(3-oxo-3-arylpropyl)-2,3- dihydro-1H-inden-1-one derivatives has been achieved via Pd/C-mediated arylation followed by I2-mediated regioselective hydration of 2-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-ones. A wide variety of 3-aryl substituted 2-propynyl indanone derivatives were conveniently prepared by using 10% Pd/C-PPh3-CuI as a catalyst system, some of which were used to prepare the corresponding ketones via alkyne hydration in the presence of catalytic I2. In an in vitro study a representative compound showed inhibition of PDE4B (phosphodiesterase type 4B) and binding with this protein in silico

OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS

A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and - CHR3- is =CH- linked by the double bond to cyclopentanone; or - (-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR', CN, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halogen, heteroaryl; and the pharmaceutical salts and stereisomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors

Four series of novel heterodimers comprised of donepezil and huperzine A (HupA) fragments were designed, synthesized, and evaluated in search of potent acetylcholinesterase (AChE) inhibitors as potential therapeutic treatment for Alzheimer's disease. Hete

Process for the preparation of donepezil

The invention provides a process for the preparation of a compound of the formula 6 comprising the hydrolysis and decarboxylation of a compound of the formula 5 according to the reaction: wherein R and R2 independently a C1-C4 alkyl group or an aralkyl group.

Process for the preparation of Donepezil

The invention provides a process for the preparation of a compound of the formula 6 comprising the hydrolysis and decarboxylation of a compound of the formula 5 according to the reaction: wherein R and R2 are independently a C1-C4 alkyl group or an aralkyl group.